<DOC>
	<DOCNO>NCT00000841</DOCNO>
	<brief_summary>To determine clinical efficacy indinavir sulfate placebo combination zidovudine ( AZT ) lamivudine ( 3TC ) AIDS patient . Protease inhibitor indinavir sulfate may effective patient advance HIV disease receive prior AZT therapy . Since study suggest triple drug therapy may advantage monotherapy two drug therapy , combination indinavir sulfate AZT 3TC evaluate .</brief_summary>
	<brief_title>A Study Indinavir Sulfate Plus Zidovudine ( AZT ) Plus Lamivudine HIV-Infected Patients Who Have Taken AZT Six More Months</brief_title>
	<detailed_description>Protease inhibitor indinavir sulfate may effective patient advance HIV disease receive prior AZT therapy . Since study suggest triple drug therapy may advantage monotherapy two drug therapy , combination indinavir sulfate AZT 3TC evaluate . Patients randomized receive open-label AZT 3TC without indinavir sulfate least 48 week . Patients develop intolerance AZT progressive disease 24 week study may substitute stavudine ( d4T ) AZT . Patients follow week 4 , 8 , 16 , 24 , 32 , 40 , 48 every 8 week thereafter week 96 . [ AS PER 02/25/97 AMENDMENT : Accrual halt interim analysis show triple therapy superior double-agent therapy . An open label extension phase add period 06/30/97 . Patients randomized AZT/3TC give option continue assign ACTG 320 study drug , cross open-label indinavir , permanently discontinue study therapy go study . Patients randomize AZT/3TC plus indinavir crossed therapy give option continue currently assign therapy . It strongly suggest patient AZT/3TC wish receive open-label indinavir consider change nucleoside analog component regimen possible . ] [ AS PER 06/06/97 AMENDMENT : The availability current ACTG 320 treatment extend approximately 12 additional week ( beyond 09/30/97 ) . This extension allow patient continue receive study medication ACTG 372 open accrual ( rollover protocol subject originally randomize triple drug component ACTG 320 cross due confirm study endpoint finalize ) . ] [ AS PER 09/15/97 AMENDMENT : Open-label therapy provide 90 day beyond enrollment first subject ACTG 372 . ]</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : PCP prophylaxis . Allowed : Topical oral antifungal agent ( oral ketoconazole ) . Approved agent opportunistic infection . Antibiotics unless specifically exclude . Systemic corticosteroids 21 day . Vitamins . Recombinant erythropoietin . GCSF . Regularly prescribed medication allergy medication , antidepressant , antipyretic , analgesic , oral contraceptive , megestrol , testosterone . Concurrent Treatment : Allowed : Acupuncture . Visualization technique . Patients must : HIV infection . CD4 count &lt; = 200 cells/mm3 . At least 6 month total prior AZT therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancy require systemic therapy minimal Kaposi 's sarcoma . Concurrent Medication : Excluded : Antiretrovirals study drug . Rifabutin rifampin . Investigational drug indinavir sulfate . Systemic cytotoxic chemotherapy . Oral ketoconazole . Chronic systemic corticosteroid . Herbal therapy . Patients follow prior condition exclude : Unexplained temperature &gt; 38.5 C 7 day within 30 day prior study entry . Chronic diarrhea persist 15 day within 30 day prior study entry . History acute chronic pancreatitis . Acute hepatitis within 30 day prior study entry . Grade 2 bad bilateral peripheral neuropathy within 60 day prior study entry . Doselimiting intolerance prior AZT 600 mg/day . Prior Medication : Excluded : More 1 week prior 3TC . Any prior protease inhibitor . Rifampin rifabutin within 14 day prior study entry . Excluded within 30 day prior study entry : Erythropoietin . GCSF GMCSF . Nonnucleoside reverse transcriptase inhibitor . Interferons . Interleukins . HIV vaccine . Any experimental therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
</DOC>